8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 27, 2026·SEC
ALX Oncology Holdings Inc.(ALXO)Earnings, Financials & Key Ratios
ALXO•NASDAQ
Price updated Jun 19, 2026
AboutALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$103M+27.0%
- Net Income-$102M+24.6%
- EPS (Diluted)-1.90+26.4%
- ROE-145.7%-63.9%
ALXO Key Insights
ALX Oncology Holdings Inc. (ALXO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 17.3% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ALXO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALXO Price & Volume
ALX Oncology Holdings Inc. (ALXO) stock price & volume — 10-year historical chart
Loading chart...
ALXO Growth Metrics
ALX Oncology Holdings Inc. (ALXO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.2%
Return on Capital
10 Years-95.77%
5 Years-68.56%
3 Years-94.05%
Last Year-127.03%
ALXO Recent Earnings
ALX Oncology Holdings Inc. (ALXO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.17-13.3%
$0.15
Rev
—
—
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.42-10.5%
$0.38
Rev
—
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.41-10.8%
$0.37
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.49-6.5%
$0.46
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.17vs $0.15-13.3% | — |
| Q1 2026 | Feb 27, 2026 | $0.42vs $0.38-10.5% | — |
| Q4 2025 | Nov 7, 2025 | $0.41vs $0.37-10.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.49vs $0.46-6.5% | — |
Based on last 12 quarters of dataView full earnings history →
ALXO Peer Comparison
ALX Oncology Holdings Inc. (ALXO) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare ALXO vs Peers
ALX Oncology Holdings Inc. (ALXO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALXO Income Statement
ALX Oncology Holdings Inc. (ALXO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.07M | 4.8M | 1.18M | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | 132.03% | -75.35% | -100% | - | - | - | - | - |
Cost of Goods Sold | 1.88M | 4.36M | 1.07M | 0 | 0 | 0 | 0 | 0 | 150K |
COGS % of Revenue | 90.95% | 90.91% | 90.95% | - | - | - | - | - | - |
Gross Profit | 187K▲ 0% | 436K▲ 133.2% | 107K▼ 75.5% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -150K▲ 0% |
Gross Margin % | 9.05% | 9.09% | 9.05% | - | - | - | - | - | - |
Gross Profit Growth % | - | 133.16% | -75.46% | -100% | - | - | - | - | - |
Operating Expenses | 13.87M | 19.62M | 43.77M | 83.56M | 127.44M | 170.28M | 142.47M | 104.02M | 91.02M |
OpEx % of Revenue | 671.07% | 409.07% | 3703.05% | - | - | - | - | - | - |
Selling, General & Admin | 2.6M | 3.31M | 14.81M | 23.39M | 29.04M | 28.48M | 26.09M | 23.85M | 21.28M |
SG&A % of Revenue | 125.83% | 69.08% | 1252.88% | - | - | - | - | - | - |
Research & Development | 11.27M | 16.31M | 28.96M | 60.17M | 98.4M | 141.79M | 116.37M | 77M | 66.71M |
R&D % of Revenue | 545.23% | 339.99% | 2450.17% | - | - | - | - | - | - |
Other Operating Expenses | -2K | 0 | 0 | 0 | 0 | 0 | 0 | 3.17M | 850K |
Operating Income | -13.68M▲ 0% | -19.18M▼ 40.2% | -43.66M▼ 127.6% | -83.56M▼ 91.4% | -127.44M▼ 52.5% | -170.28M▼ 33.6% | -142.47M▲ 16.3% | -104.02M▲ 27.0% | -91.17M▲ 0% |
Operating Margin % | -662.02% | -399.98% | -3693.99% | - | - | - | - | - | - |
Operating Income Growth % | - | -40.19% | -127.61% | -91.36% | -52.52% | -33.62% | 16.33% | 26.99% | - |
EBITDA | -13.25M | -18.75M | -43.46M | -83.5M | -127.09M | -169.44M | -141.59M | -103.31M | -90.52M |
EBITDA Margin % | -641.17% | -391.03% | -3676.9% | - | - | - | - | - | - |
EBITDA Growth % | - | -41.51% | -131.74% | -92.14% | -52.2% | -33.32% | 16.43% | 27.03% | 33.27% |
D&A (Non-Cash Add-back) | 431K | 429K | 202K | 51K | 342K | 836K | 872K | 706K | 645K |
EBIT | -13.69M | -19.19M | -43.66M | -83.47M | -123.18M | -159.24M | -133.12M | -100.09M | -88.71M |
Net Interest Income | 0 | -21K | -811K | -12.91K | 4.04M | 9.08M | 7.64M | 2.36M | 2.14M |
Interest Income | 0 | 0 | 0 | 91 | 4.28M | 10.65M | 9.37M | 3.96M | 3.66M |
Interest Expense | 0 | 21K | 811K | 13K | 238K | 1.56M | 1.73M | 1.6M | 1.53M |
Other Income/Expense | -2K | -26K | -1.84M | 71K | 4.02M | 9.47M | 7.62M | 2.33M | 2.3M |
Pretax Income | -13.69M▲ 0% | -19.21M▼ 40.4% | -45.5M▼ 136.9% | -83.48M▼ 83.5% | -123.42M▼ 47.8% | -160.81M▼ 30.3% | -134.85M▲ 16.1% | -101.69M▲ 24.6% | -88.87M▲ 0% |
Pretax Margin % | -662.12% | -400.52% | -3849.32% | - | - | - | - | - | - |
Income Tax | 45K | 34K | 241K | -21K | 64K | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.33% | -0.18% | -0.53% | 0.03% | -0.05% | 0% | 0% | 0% | 0% |
Net Income | -13.73M▲ 0% | -19.24M▼ 40.1% | -45.74M▼ 137.7% | -83.46M▼ 82.5% | -123.48M▼ 47.9% | -160.81M▼ 30.2% | -134.85M▲ 16.1% | -101.69M▲ 24.6% | -88.87M▲ 0% |
Net Margin % | -664.3% | -401.23% | -3869.71% | - | - | - | - | - | - |
Net Income Growth % | - | -40.14% | -137.7% | -82.47% | -47.95% | -30.23% | 16.14% | 24.59% | 31.65% |
Net Income (Continuing) | -13.73M | -19.24M | -45.74M | -83.46M | -123.48M | -160.81M | -134.85M | -101.69M | -88.87M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.63▲ 0% | -0.88▼ 39.7% | -1.28▼ 45.5% | -2.07▼ 61.7% | -3.03▼ 46.4% | -3.74▼ 23.4% | -2.58▲ 31.0% | -1.90▲ 26.4% | -1.64▲ 0% |
EPS Growth % | - | -39.68% | -45.45% | -61.72% | -46.38% | -23.43% | 31.02% | 26.36% | 33.2% |
EPS (Basic) | -0.63 | -0.88 | -1.28 | -2.07 | -3.03 | -3.74 | -2.58 | -1.90 | - |
Diluted Shares Outstanding | 21.95M | 21.95M | 39.84M | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M | 54.28M |
Basic Shares Outstanding | 21.95M | 21.95M | 39.84M | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M | 54.28M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ALXO Balance Sheet
ALX Oncology Holdings Inc. (ALXO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 10.21M | 9.81M | 435.99M | 367.02M | 270.97M | 188.66M | 134.35M | 50.73M | 145.56M |
Cash & Short-Term Investments | 8.26M | 9.02M | 434.22M | 363.67M | 266.21M | 182.74M | 127.76M | 44.79M | 140.32M |
Cash Only | 8.26M | 9.02M | 434.22M | 363.67M | 48.82M | 22.41M | 17.57M | 16.37M | 32.28M |
Short-Term Investments | 0 | 0 | 0 | 0 | 217.38M | 160.33M | 110.19M | 28.42M | 108.04M |
Accounts Receivable | 932K | 536K | 0 | 0 | 0 | 0 | 892K | 298K | 0 |
Days Sales Outstanding | 164.58 | 40.79 | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 4.76M | 5.92M | 5.7M | 5.64M | 5.24M |
Total Non-Current Assets | 956K | 867K | 62K | 13.16M | 35.52M | 53.89M | 13.42M | 8.32M | 32.76M |
Property, Plant & Equipment | 956K | 860K | 52K | 3.47M | 9.81M | 10.84M | 9.63M | 1.2M | 1.05M |
Fixed Asset Turnover | 2.16x | 5.58x | 22.73x | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 16.7M | 35.41M | 3.52M | 3.49M | 42.35M |
Other Non-Current Assets | 0 | 7K | 10K | 9.69M | 9.01M | 7.64M | 267K | 3.63M | 2.93M |
Total Assets | 11.16M▲ 0% | 10.68M▼ 4.4% | 436.05M▲ 3984.4% | 380.18M▼ 12.8% | 306.49M▼ 19.4% | 242.55M▼ 20.9% | 147.78M▼ 39.1% | 59.05M▼ 60.0% | 178.33M▲ 0% |
Asset Turnover | 0.19x | 0.45x | 0.00x | - | - | - | - | - | 0.00x |
Asset Growth % | - | -4.37% | 3984.43% | -12.81% | -19.38% | -20.86% | -39.08% | -60.04% | -123.59% |
Total Current Liabilities | 1.87M | 4.98M | 6.2M | 15.29M | 28.32M | 36M | 18.5M | 24.55M | 20.18M |
Accounts Payable | 697K | 3.75M | 4K | 3.76M | 8.07M | 8.59M | 4.5M | 4.91M | 3.85M |
Days Payables Outstanding | 135.32 | 313.77 | 1.36 | - | - | - | - | - | 12.32K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 435K | 5.22M | 5.22M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 369K | 1.06M | 2.13M | 3.53M | 4.72M | 6.7M | 5.97M | 14.42M | 11.11M |
Current Ratio | 5.45x | 1.97x | 70.28x | 24.00x | 9.57x | 5.24x | 7.26x | 2.07x | 7.21x |
Quick Ratio | 5.45x | 1.97x | 70.28x | 24.00x | 9.57x | 5.24x | 7.26x | 2.07x | 7.21x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 136K | 5.97M | 5K | 1.84M | 14.7M | 16.84M | 15.66M | 8.51M | 6.8M |
Long-Term Debt | 0 | 5.42M | 0 | 0 | 9.39M | 9.64M | 9.47M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 5.98M | 5.16M | 0 | 4.13M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 412K | 5K | 1.84M | 5.31M | 1.22M | 1.03M | 8.51M | 6.8M |
Total Liabilities | 2.01M | 10.95M | 6.21M | 17.13M | 43.02M | 52.84M | 34.16M | 33.06M | 26.98M |
Total Debt | 0 | 5.42M | 0 | 742K | 10.43M | 17.2M | 16.98M | 5.22M | 5.22M |
Net Debt | -8.26M | -3.6M | -434.22M | -362.93M | -38.39M | -5.21M | -589K | -11.16M | -27.07M |
Debt / Equity | - | - | - | 0.00x | 0.04x | 0.09x | 0.15x | 0.20x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.06x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.30x |
Interest Coverage | - | -913.71x | -53.84x | -6420.85x | -517.56x | -101.75x | -76.99x | -62.48x | -58.09x |
Total Equity | 9.15M▲ 0% | -276K▼ 103.0% | 429.85M▲ 155840.9% | 363.05M▼ 15.5% | 263.46M▼ 27.4% | 189.71M▼ 28.0% | 113.62M▼ 40.1% | 25.98M▼ 77.1% | 151.35M▲ 0% |
Equity Growth % | - | -103.01% | 155840.94% | -15.54% | -27.43% | -27.99% | -40.11% | -77.13% | -132.54% |
Book Value per Share | 0.42 | -0.01 | 10.79 | 9.01 | 6.47 | 4.41 | 2.18 | 0.48 | 2.79 |
Total Shareholders' Equity | 9.15M | -276K | 429.85M | 363.05M | 263.46M | 189.71M | 113.62M | 25.98M | 151.35M |
Common Stock | 3K | 3K | 40K | 41K | 41K | 50K | 53K | 54K | 135K |
Retained Earnings | -53.54M | -72.78M | -118.52M | -201.99M | -325.47M | -486.27M | -621.12M | -722.82M | -740.74M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.02M | 0 | 0 | 0 | -845K | 256K | 275K | 28K | -245K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALXO Cash Flow Statement
ALX Oncology Holdings Inc. (ALXO) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.19M | -14.25M | -38.29M | -68.1M | -89.22M | -130.36M | -121.91M | -84.14M | -78.13M |
Operating CF Margin % | -638.12% | -297.1% | -3239.34% | - | - | - | - | - | - |
Operating CF Growth % | - | -8.03% | -168.71% | -77.86% | -31.02% | -46.11% | 6.48% | 30.98% | 109.7% |
Net Income | -13.73M | -19.24M | -45.74M | -83.46M | -123.48M | -160.81M | -134.85M | -101.69M | -88.87M |
Depreciation & Amortization | 431K | 429K | 202K | 51K | 342K | 836K | 872K | 706K | 645K |
Stock-Based Compensation | 269K | 297K | 5.44M | 13.91M | 23.84M | 26.27M | 27.09M | 12.58M | 7.36M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.33M | 11K | 1.57M | 5.42M | 228K | -4.96M | -2.6M | 3.93M | 6.68M |
Working Capital Changes | -159K | 4.26M | 247K | -4.03M | 9.85M | 8.3M | -12.43M | 336K | -3.95M |
Change in Receivables | -932K | 396K | 536K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -269K | 2.98M | -3.74M | 3.29M | 4.51M | 458K | -4.02M | 421K | -233K |
Cash from Investing | -653K | -353K | 610K | -4.92M | -235.42M | 44.66M | 86.26M | 82.59M | -50.09M |
Capital Expenditures | -653K | -353K | -31K | -4.92M | -1.43M | -1.27M | -447K | -212K | -202K |
CapEx % of Revenue | 31.59% | 7.36% | 2.62% | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 233.99K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 641K | 0 | -233.99K | 0 | 0 | 0 | 0 |
Cash from Financing | 1K | 15.36M | 462.88M | 2.47M | 9.86M | 59.29M | 30.82M | 362K | 139.89M |
Debt Issued (Net) | 0 | 5.92M | 0 | -281K | 9.61M | -388K | -827K | -1.36M | -2.67M |
Equity Issued (Net) | -6K | 9.43M | 472.94M | 2.75M | 903K | 58.89M | 31.64M | 1.73M | 142.56M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 7K | 10K | -10.05M | 0 | -655K | 792K | 0 | 0 | 1K |
Net Change in Cash | -13.84M▲ 0% | 755K▲ 105.5% | 425.2M▲ 56218.1% | -70.55M▼ 116.6% | -314.78M▼ 346.2% | -26.42M▲ 91.6% | -4.84M▲ 81.7% | -1.19M▲ 75.3% | 11.67M▲ 0% |
Free Cash Flow | -13.84M▲ 0% | -14.6M▼ 5.5% | -38.32M▼ 162.4% | -73.02M▼ 90.6% | -90.65M▼ 24.1% | -131.64M▼ 45.2% | -122.36M▲ 7.0% | -84.35M▲ 31.1% | -78.33M▲ 0% |
FCF Margin % | -669.71% | -304.46% | -3241.96% | - | - | - | - | - | - |
FCF Growth % | - | -5.48% | -162.43% | -90.56% | -24.14% | -45.22% | 7.05% | 31.06% | 28.15% |
FCF per Share | -0.63 | -0.67 | -0.96 | -1.81 | -2.23 | -3.06 | -2.35 | -1.57 | -1.44 |
FCF Conversion (FCF/Net Income) | 0.96x | 0.74x | 0.84x | 0.82x | 0.72x | 0.81x | 0.90x | 0.83x | 0.88x |
Interest Paid | 0 | 0 | 427K | 11K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 47K | 274K | 0 | 0 | 0 | 0 | 0 |
ALXO Key Ratios
ALX Oncology Holdings Inc. (ALXO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -433.45% | -21.3% | -21.05% | -39.42% | -70.97% | -88.91% | -145.7% | -124.06% |
Return on Invested Capital (ROIC) | - | - | -50537.3% | -84.88% | -62.36% | -71.82% | -122.04% | -120.96% |
Gross Margin | 9.09% | 9.05% | - | - | - | - | - | - |
Net Margin | -401.23% | -3869.71% | - | - | - | - | - | - |
Debt / Equity | - | - | 0.00x | 0.04x | 0.09x | 0.15x | 0.20x | 0.03x |
Interest Coverage | -913.71x | -53.84x | -6420.85x | -517.56x | -101.75x | -76.99x | -62.48x | -58.09x |
FCF Conversion | 0.74x | 0.84x | 0.82x | 0.72x | 0.81x | 0.90x | 0.83x | 0.88x |
Revenue Growth | 132.03% | -75.35% | -100% | - | - | - | - | - |
Related:ALXO Dividend History·ALXO Revenue History·ALXO Price History·ALXO P/E History·ALXO Financial Ratios·ALXO Institutional Holders
ALXO SEC Filings & Documents
ALX Oncology Holdings Inc. (ALXO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALXO Frequently Asked Questions
ALX Oncology Holdings Inc. (ALXO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ALX Oncology Holdings Inc. (ALXO) grew revenue by 0.0% over the past year. Growth has been modest.
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $88.9M for fiscal year 2025.
Dividend & Returns
ALX Oncology Holdings Inc. (ALXO) has a return on equity (ROE) of -145.7%. Negative ROE indicates the company is unprofitable.
ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $78.3M in fiscal year 2025, likely due to heavy capital investments.